Phase 2 Study of EPI-743 in Children With Pearson Syndrome

Pearson Syndrome Clinical Trial

Official title:
An Open-Label Phase 2 Safety and Efficacy Study of EPI-743 (VincerinoneTM) in Children With Pearson Syndrome

Status Terminated

Clinical Trial Summary

Treatment of Pediatric Subjects with Pearson syndrome

Clinical Trial Description

If effective, treatment with EPI-743 should result in a significant reduction in occurrence of sepsis, metabolic crisis, hepatic failure and transfusion dependence. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02104336
Study type	Interventional
Source	Edison Pharmaceuticals Inc
Contact
Status	Terminated
Phase	Phase 2
Start date	August 31, 2014
Completion date	February 29, 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02327364` - Natural History of Pearson Syndrome
Recruiting	`NCT05029843` - SLSMDS Natural History Study
Recruiting	`NCT06017869` - Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-201 in Pediatric Patients With Pearson Syndrome	Phase 1
Completed	`NCT03384420` - A Study to Evaluate the Safety and Therapeutic Effects of Transplantation of MNV-BM-BLD in Pediatric Patients With Pearson Syndrome	Phase 1/Phase 2
Recruiting	`NCT05554835` - Global Registry and Natural History Study for Mitochondrial Disorders